304 related articles for article (PubMed ID: 17082774)
21. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner.
Isenberg JS; Ridnour LA; Perruccio EM; Espey MG; Wink DA; Roberts DD
Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13141-6. PubMed ID: 16150726
[TBL] [Abstract][Full Text] [Related]
22. Thrombospondins as anti-angiogenic therapeutic agents.
Vailhé B; Feige JJ
Curr Pharm Des; 2003; 9(7):583-8. PubMed ID: 12570805
[TBL] [Abstract][Full Text] [Related]
23. Beta 1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides.
Wilson KE; Li Z; Kara M; Gardner KL; Roberts DD
J Immunol; 1999 Oct; 163(7):3621-8. PubMed ID: 10490955
[TBL] [Abstract][Full Text] [Related]
24. [Thrombospondins: multimodular proteins with angiostatic function].
Feige JJ
Pathol Biol (Paris); 1999 Apr; 47(4):339-44. PubMed ID: 10372402
[TBL] [Abstract][Full Text] [Related]
25. Expression of thrombospondin-1 modulates the angioinflammatory phenotype of choroidal endothelial cells.
Fei P; Zaitoun I; Farnoodian M; Fisk DL; Wang S; Sorenson CM; Sheibani N
PLoS One; 2014; 9(12):e116423. PubMed ID: 25548916
[TBL] [Abstract][Full Text] [Related]
26. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
Castle VP; Dixit VM; Polverini PJ
Lab Invest; 1997 Jul; 77(1):51-61. PubMed ID: 9251678
[TBL] [Abstract][Full Text] [Related]
27. The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways.
Tan Ide A; Ricciardelli C; Russell DL
Int J Cancer; 2013 Nov; 133(10):2263-76. PubMed ID: 23444028
[TBL] [Abstract][Full Text] [Related]
28. CD36-TSP-HRGP interactions in the regulation of angiogenesis.
Silverstein RL; Febbraio M
Curr Pharm Des; 2007; 13(35):3559-67. PubMed ID: 18220792
[TBL] [Abstract][Full Text] [Related]
29. Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo.
Calzada MJ; Zhou L; Sipes JM; Zhang J; Krutzsch HC; Iruela-Arispe ML; Annis DS; Mosher DF; Roberts DD
Circ Res; 2004 Mar; 94(4):462-70. PubMed ID: 14699013
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the extracellular matrix patterning of thrombospondins by actin dynamics and thrombospondin oligomer state.
Hellewell AL; Gong X; Schärich K; Christofidou ED; Adams JC
Biosci Rep; 2015 May; 35(3):. PubMed ID: 26182380
[TBL] [Abstract][Full Text] [Related]
31. ADAMTS1: a matrix metalloprotease with angioinhibitory properties.
Iruela-Arispe ML; Carpizo D; Luque A
Ann N Y Acad Sci; 2003 May; 995():183-90. PubMed ID: 12814950
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer.
Gustavsson H; Jennbacken K; Welén K; Damber JE
Prostate; 2008 Feb; 68(2):161-70. PubMed ID: 18076023
[TBL] [Abstract][Full Text] [Related]
33. Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1.
Yu H; Tyrrell D; Cashel J; Guo NH; Vogel T; Sipes JM; Lam L; Fillit HM; Hartman J; Mendelovitz S; Panel A; Roberts DD
Arch Biochem Biophys; 2000 Feb; 374(1):13-23. PubMed ID: 10640391
[TBL] [Abstract][Full Text] [Related]
34. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
35. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.
Filleur S; Volpert OV; Degeorges A; Voland C; Reiher F; Clézardin P; Bouck N; Cabon F
Genes Dev; 2001 Jun; 15(11):1373-82. PubMed ID: 11390357
[TBL] [Abstract][Full Text] [Related]
36. Two-hybrid analysis reveals multiple direct interactions for thrombospondin 1.
Aho S; Uitto J
Matrix Biol; 1998 Oct; 17(6):401-12. PubMed ID: 9840442
[TBL] [Abstract][Full Text] [Related]
37. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.
Quesada AJ; Nelius T; Yap R; Zaichuk TA; Alfranca A; Filleur S; Volpert OV; Redondo JM
Cell Death Differ; 2005 Jun; 12(6):649-58. PubMed ID: 15818399
[TBL] [Abstract][Full Text] [Related]
38. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium.
Iruela-Arispe ML; Porter P; Bornstein P; Sage EH
J Clin Invest; 1996 Jan; 97(2):403-12. PubMed ID: 8567961
[TBL] [Abstract][Full Text] [Related]
39. Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells.
Karagiannis ED; Popel AS
Int J Biochem Cell Biol; 2007; 39(12):2314-23. PubMed ID: 17707681
[TBL] [Abstract][Full Text] [Related]
40. Thrombospondins 1 and 2 are important for afferent synapse formation and function in the inner ear.
Mendus D; Sundaresan S; Grillet N; Wangsawihardja F; Leu R; Müller U; Jones SM; Mustapha M
Eur J Neurosci; 2014 Apr; 39(8):1256-67. PubMed ID: 24460873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
